89bio, Inc. (ETNB) Financials
ETNB Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 596.3 million | 60.0 million |
2023-09-30 | 460.1 million | 49.9 million |
2023-06-30 | 492.5 million | 50.5 million |
2023-03-31 | 494.3 million | 48.5 million |
ETNB Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -34.3 million | 4.0 million |
2023-09-30 | -30.4 million | 4.4 million |
2023-06-30 | -34.4 million | 4.1 million |
2023-03-31 | -30.1 million | 3.6 million |
ETNB Net Income
No data available :(
ETNB Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 578.9 million | - | 2.3 million |
2023-09-30 | 448.3 million | - | 229000 |
2023-06-30 | 478.0 million | 24.5 million | 271000 |
2023-03-31 | 480.9 million | 24.3 million | 313000 |
ETNB Shares Outstanding
ETNB Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 4000 | 33.6 million | 7.6 million | 16000 |
2023-09-30 | - | 31.4 million | 7.9 million | - |
2023-06-30 | - | 34.9 million | 7.2 million | - |
2023-03-31 | - | 22.3 million | 6.2 million | - |
ETNB Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 16000 |
2023-09-30 | - | 10000 |
2023-06-30 | - | 52000 |
2023-03-31 | - | 55000 |
ETNB
Price: $8.26
52 week price:
Earnings Per Share: -2.00 USD
P/E Ratio: -5.21
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.6 million
Market Capitalization: 1.0 billion